List of Excipients in Branded Drug FEMLYV

FEMLYV Excipient Strategy and Commercial Opportunities

Last updated: August 29, 2026

FEMLYV is a 1 mg norethindrone acetate/0.02 mg ethinyl estradiol orally disintegrating tablet marketed by Exeltis USA. Its commercial differentiation comes from dosage-form convenience rather than a new active ingredient. The strongest excipient opportunities are taste masking, rapid disintegration, moisture control, tablet robustness, and packaging designed for highly moisture-sensitive low-dose hormones.

What is FEMLYV and why does its excipient platform matter?

FEMLYV is an orally disintegrating combined hormonal contraceptive. The tablet is intended to disintegrate in the mouth without water, which can improve portability and ease of administration compared with conventional swallowed tablets.[1]

Each active tablet contains:

Product attribute	FEMLYV
Active ingredients	Norethindrone acetate and ethinyl estradiol
Strength	1 mg/0.02 mg
Dosage form	Orally disintegrating tablet
Therapeutic category	Combined oral contraceptive
Applicant/marketer	Exeltis USA, Inc.
FDA pathway	505(b)(2) or 505(j) status must be confirmed from the current FDA approval record; the product is not an NCE
Primary formulation challenge	Delivering rapid oral disintegration while controlling hormone taste, dose uniformity, friability, and moisture exposure

For FEMLYV, excipients are part of the product proposition. A conventional tablet can rely on swallowing to avoid prolonged oral exposure. An orally disintegrating tablet cannot. The formulation must manage the sensory profile during wetting and disintegration, particularly because ethinyl estradiol and norethindrone acetate are potent, low-dose compounds that can create dose-uniformity and content-uniformity risks.

What excipients are used in FEMLYV?

Public product labeling identifies inactive ingredients used in the commercial tablet. The label should be treated as the controlling source for the marketed formulation and should be reconciled against the current DailyMed record and FDA approval documents before making a regulatory or competitive decision.[1]

Reported excipient categories include:

Excipient category	Commercial function in an ODT
Mannitol or another soluble filler	Provides bulk, mouthfeel, cooling sensation, and rapid dissolution
Microcrystalline cellulose or related compression aid	Improves compactability and tablet strength
Crospovidone or another superdisintegrant	Promotes rapid liquid uptake and tablet breakup
Colloidal silicon dioxide	Improves powder flow and may reduce cohesion
Magnesium stearate	Provides lubrication during compression
Sweetener	Reduces bitterness and improves acceptability
Flavor	Supports sensory masking and patient acceptability

The exact grade, supplier, particle-size distribution, surface treatment, and processing history are not generally disclosed in the prescribing information. Those attributes can be commercially important. Two formulations containing the same compendial excipients may have materially different disintegration, mouthfeel, moisture uptake, and bioavailability profiles.

Which formulation characteristics are most important?

The key quality attributes are:

1. Disintegration time in the oral cavity.
2. Assay and content uniformity for both hormones.
3. Tablet hardness and friability.
4. Residual moisture and water activity.
5. Dissolution under relevant pH conditions.
6. Taste, grittiness, chalkiness, and aftertaste.
7. Stability through the labeled shelf life.
8. Packaging protection after opening or removal from the blister.

The low dose of ethinyl estradiol creates a particularly narrow formulation margin. Small segregation effects can produce meaningful relative variability in the estrogen component. Excipients with inconsistent particle size or density can therefore create manufacturing and regulatory risk even when the active ingredients are chemically stable.

How should an excipient strategy for FEMLYV be structured?

A commercially effective strategy should use a platform approach rather than a single-excipient substitution program.

1. Build a direct-compression ODT platform

A direct-compression system can reduce solvent exposure, simplify manufacturing, and support contract manufacturing. The platform should use:

• A soluble, low-hygroscopic filler for mouthfeel and tablet volume.
• A high-efficiency superdisintegrant.
• A low-level glidant for flow and die filling.
• A lubricant selected to limit dissolution retardation.
• A flavor and sweetener system compatible with hormone stability.

The primary technical tradeoff is tablet strength versus rapid disintegration. Increasing compression force can improve mechanical integrity but delay tablet breakup. Increasing superdisintegrant concentration can accelerate disintegration but increase friability, mouthfeel defects, or segregation.

2. Use co-processed excipients

Co-processed mannitol-cellulose, mannitol-crospovidone, or similar multifunctional systems can improve flow, compactability, and disintegration without requiring a large number of individual excipients. These systems offer commercial value where the manufacturer wants:

• Fewer raw-material vendors.
• Lower development time.
• More consistent scale-up.
• A narrower process window.
• Reduced sensitivity to active-powder properties.

The patent opportunity is stronger when the claim covers a defined combination of excipient grades, particle-size distributions, compression conditions, and performance thresholds rather than simply naming common excipients.

3. Treat taste masking as a separate development workstream

Taste masking is one of the most defensible opportunities in an ODT product. A viable strategy could combine:

• Sweetener and flavor optimization.
• Polymer film coating of active particles.
• Ion-exchange or adsorption technology.
• Lipid or wax-based microencapsulation.
• Spray-dried active-excipient particles.
• pH-dependent release control in the oral cavity.

The formulation must avoid delaying systemic release after swallowing. A taste-masking coating that suppresses dissolution in the mouth but also produces a slower or incomplete gastrointestinal release profile may create bioequivalence problems.

4. Optimize moisture management

Many ODT systems are moisture-sensitive because water can reduce tablet strength, accelerate disintegration during storage, or change the physical state of the excipient matrix. A moisture strategy should include:

• Low-moisture excipient grades.
• Controlled-humidity blending and compression.
• High-barrier aluminum-aluminum blisters.
• Desiccant-compatible secondary packaging where appropriate.
• Moisture sorption studies for each excipient combination.
• In-use stability testing after package opening.

Packaging is part of the formulation business case. A low-cost excipient platform that requires expensive high-barrier packaging may have less commercial value than a slightly more expensive formulation that supports a simpler package.

What commercial opportunities exist for FEMLYV excipients?

Which excipient suppliers could benefit?

The most relevant supplier opportunities are in five areas:

Opportunity	Value proposition	Commercial buyer
ODT filler systems	Better mouthfeel and compactability	Brand owner, generic manufacturer, CMO
Superdisintegrant platforms	Faster disintegration at lower loading	Formulator and tablet manufacturer
Taste-masking systems	Improved patient acceptability	Brand owner and specialty generic developer
Moisture-control excipients	Longer stability and lower packaging burden	Product developer and packaging group
Co-processed excipients	Faster scale-up and fewer formulation variables	CMO and ANDA sponsor

Supplier differentiation is strongest when supported by formulation data with low-dose hormonal actives. Generic ODT performance data using high-dose model compounds may not translate to FEMLYV because dose uniformity, potency, and taste behavior differ.

Can excipients create a generic entry opportunity?

Yes. A generic applicant could pursue an equivalent ODT using different excipients if the product meets applicable FDA requirements for pharmaceutical equivalence, bioequivalence, quality, and labeling. The commercial challenge is that an ANDA applicant cannot assume that a conventional oral contraceptive formulation can be converted directly into an ODT.

Potential generic design-around options include:

• A different soluble filler system.
• An alternative superdisintegrant.
• A different flavor and sweetener combination.
• A coated-particle taste-masking approach.
• A different blister or unit-dose package.
• A distinct compression process that produces equivalent performance.

The generic applicant must evaluate whether the active ingredients are exposed to the same gastrointestinal release conditions despite differences in oral disintegration and taste masking.

Are there licensing opportunities?

Licensing opportunities may arise around:

• Proprietary ODT excipient platforms.
• Taste-masked norethindrone acetate or ethinyl estradiol particles.
• Co-processed excipients with validated low-dose content uniformity.
• High-barrier packaging and moisture-control systems.
• Contract development and manufacturing of hormone ODTs.
• Expansion into noncontraceptive hormone products using the same platform.

The most valuable licensing package would include composition claims, manufacturing-process claims, comparative dissolution data, stability data, and human sensory data. A formulation patent based only on standard excipients in conventional ranges would usually provide weaker negotiating leverage.

What patents protect FEMLYV and its excipient formulation?

Publicly available prescribing information does not establish the complete patent estate. Patent protection must be assessed through the current FDA Orange Book, USPTO records, WIPO PatentScope, and assignee records.[1-4]

The relevant patent categories are:

Patent category	Relevance to FEMLYV
Active-ingredient patents	Limited because norethindrone acetate and ethinyl estradiol are established compounds
ODT composition patents	Potentially important if the tablet has defined excipient ratios or performance parameters
Taste-masking patents	Relevant if coated or encapsulated hormone particles are used
Manufacturing patents	May cover blending, granulation, compression, coating, or moisture-control steps
Packaging patents	May protect blister construction or stability-preserving packaging
Method-of-use patents	Could cover contraceptive use, dosing schedules, or patient populations, subject to Orange Book listing rules

The strongest formulation protection would typically require a combination of:

• Narrow excipient ranges.
• Defined particle-size or surface-area parameters.
• Specified disintegration or dissolution limits.
• Stability limits under accelerated conditions.
• A manufacturing sequence that produces a measurable product profile.

Common excipients such as mannitol, crospovidone, magnesium stearate, and colloidal silicon dioxide are difficult to protect broadly on their own. Value is more likely to reside in the combination, processing method, or performance result.

When does FEMLYV lose exclusivity?

FEMLYV does not receive new chemical entity exclusivity merely because it uses an orally disintegrating dosage form. Its regulatory exclusivity depends on the approval pathway, the regulatory findings supporting approval, and any listed patents.

Potential protections include:

• Three-year exclusivity for a new clinical investigation supporting a change or modification, if applicable.
• Five-year NCE exclusivity does not normally apply to previously approved active ingredients.
• Pediatric exclusivity, if separately awarded.
• Listed patents covering the formulation, method of use, or other eligible subject matter.

The exact loss-of-exclusivity date cannot be determined from the product name alone. It requires the current FDA approval record and Orange Book patent and exclusivity entries. Patent expiration also depends on patent number, priority date, patent-term adjustment, patent-term extension, terminal disclaimers, and any litigation outcome.

What is the FDA and Orange Book status of FEMLYV?

FEMLYV is an FDA-approved prescription oral contraceptive, according to its U.S. labeling.[1] Its Orange Book status should be reviewed for:

• Approved NDA number.
• Listed patents.
• Pediatric exclusivity.
• Product-specific exclusivity.
• Therapeutic-equivalence information.
• Any changes in patent listing or exclusivity status.

For a generic applicant, the likely route is an ANDA if the reference product is eligible for an ANDA and the applicant can demonstrate pharmaceutical equivalence and bioequivalence. A 505(b)(2) route may be relevant for a product with a materially different formulation, delivery system, or clinical use that cannot rely fully on the reference product's data.

What Paragraph IV and litigation risks exist?

A Paragraph IV challenge could target:

• An ODT composition patent.
• A taste-masking composition.
• A manufacturing process.
• A method-of-use patent listed in the Orange Book.
• A formulation-specific patent that limits a generic ODT design.

The principal litigation questions would be infringement, validity, and whether the claims cover a generic formulation using different excipients. Claims directed to functional results, such as rapid disintegration or stability, can create uncertainty if the generic product meets the result through a different excipient system.

A conventional swallowed generic contraceptive is not necessarily a direct substitute for FEMLYV from a dosage-form perspective. A generic sponsor seeking FEMLYV substitution would need to address the reference product's orally disintegrating characteristics and regulatory requirements.

No verified public litigation or settlement terms should be assumed without a current PACER, FDA, and Orange Book review. Settlement agreements could affect the earliest authorized generic launch date, but those terms are not established by the label alone.

Is biosimilar risk relevant to FEMLYV?

No. FEMLYV contains small-molecule hormones, not a biologic. Biosimilar regulation under the Public Health Service Act is not the relevant competitive pathway. The commercial threat is from generic oral contraceptives, including conventional tablets, chewable products, and other orally disintegrating formulations.

How strong is the FEMLYV formulation opportunity?

The formulation opportunity is commercially meaningful but technically narrower than a new active pharmaceutical ingredient.

Dimension	Assessment
Active-ingredient differentiation	Low
Patient-convenience differentiation	High
Excipient differentiation	Moderate to high
Taste-masking value	High
Manufacturing complexity	Moderate
Generic design-around risk	Moderate
Patent strength	Dependent on claim specificity and public patent coverage
Packaging dependence	High
Biosimilar risk	Not applicable
Conventional generic substitution risk	High over the long term

The platform has the greatest value if it can support additional hormone products, emergency contraception, menopause therapies, pediatric medicines, or other drugs where water-free administration and sensory acceptance affect adherence.

What revenue exposure and competitive opportunities should investors track?

Public product-specific revenue for FEMLYV should not be inferred from total Exeltis or parent-company sales. The most relevant commercial indicators are:

• Prescription growth.
• Refill persistence.
• Retail and specialty-pharmacy distribution.
• Payer coverage and copay levels.
• Contraceptive access programs.
• Unit-dose packaging costs.
• Generic ODT development activity.
• New product launches using comparable ODT technology.
• Patent and exclusivity updates.

The commercial proposition depends on whether patients, prescribers, and payers value water-free administration enough to support a premium over conventional generic contraceptives. Excipient suppliers can participate without owning the finished product by offering validated ODT platforms, taste-masking technologies, or moisture-resistant packaging systems.

Key Takeaways

• FEMLYV's differentiation is its orally disintegrating format, not a new active ingredient.
• Excipients directly affect the product's taste, disintegration, dose uniformity, stability, and packaging requirements.
• The highest-value technical opportunities are taste masking, co-processed ODT systems, moisture control, and low-dose hormone content uniformity.
• Generic applicants can potentially design around the formulation with different fillers, superdisintegrants, flavors, coatings, or packaging.
• FEMLYV is exposed to generic competition, not biosimilar competition.
• Patent value will depend on formulation specificity, process claims, performance limitations, and Orange Book eligibility.
• Exact exclusivity and patent-expiration dates require current FDA and USPTO records and should not be inferred from the product label.
• The excipient platform could support licensing and line-extension opportunities beyond contraception.

FAQs

Can mannitol be replaced in a FEMLYV generic?

Yes. A generic sponsor may use another suitable filler if the resulting product meets regulatory, bioequivalence, quality, taste, disintegration, and stability requirements. The replacement may affect mouthfeel, hygroscopicity, compression behavior, and dissolution.

Does a different flavor avoid FEMLYV formulation patents?

Not necessarily. A patent may cover the entire excipient system, a taste-masking process, defined performance criteria, or a broader ODT composition. Changing flavor alone may not avoid infringement.

Is FEMLYV suitable for an authorized generic strategy?

Potentially, but commercial viability depends on Orange Book status, exclusivity, patent barriers, manufacturing economics, payer demand, and whether the authorized generic preserves the ODT user experience.

What packaging is most commercially appropriate for an ethinyl estradiol ODT?

A high-barrier unit-dose blister is generally the most defensible starting point because it limits moisture exposure and supports portability. Final selection requires stability and package-performance data.

Can the FEMLYV excipient platform be used for pediatric medicines?

Potentially. The ODT platform may be useful for pediatric products, but taste, dose flexibility, excipient exposure, tablet size, choking risk, and age-specific administration requirements would need separate evaluation.

References

1. U.S. Food and Drug Administration. (2024). FEMLYV (norethindrone acetate and ethinyl estradiol) orally disintegrating tablets: Prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.
3. U.S. Food and Drug Administration. (n.d.). FDA drug approval databases and exclusivity information.
4. U.S. Patent and Trademark Office. (n.d.). Patent Center and Patent Public Search.